Asset Details
Do you wish to reserve the book?
Selinexor: First Global Approval
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Selinexor: First Global Approval
Do you wish to request the book?
Selinexor: First Global Approval
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Selinexor: First Global Approval
2019
Overview
Selinexor (XPOVIO™) is a first-in-class, oral, small molecule Exportin-1 (XPO1) inhibitor that is being developed by Karyopharm Therapeutics for the treatment of cancer. Selinexor (in combination with dexamethasone) received accelerated approval in the USA in July 2019 for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM). Selinexor is also undergoing clinical development in a wide range of haematological and solid cancers. This article summarizes the milestones in the development of selinexor leading to this first approval for RRMM.
Publisher
Springer International Publishing,Springer Nature B.V
Subject
/ Animals
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Cancer
/ Disease
/ Humans
/ Hydrazines - therapeutic use
/ Karyopherins - antagonists & inhibitors
/ Leukemia
/ Lymphoma
/ Medicine
/ Multiple Myeloma - drug therapy
/ Multiple Myeloma - metabolism
/ Proteins
/ Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors
/ Tumors
